Follow The Filings

OGEN Oragenics

Oragenics earnings company data as of 9:01 AM ET 10/23

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 6 Nov EPS — — —
Rev — — —
FY2026 Q2 13 Aug EPS — -0.57 —
Rev — — —

Insider trades

Open-market buys and sales by OGEN's executives, directors and 10% owners in the last 12 months, from their Form 4s

All OGEN insider trades
  • None no insider bought on the open market
  • $198 sold by 1 insider outside a trading plan
  • None no planned (10b5-1) sales
  1. Fred Telling Director
    Sale
    $198 210 shares at $0.9400 18% of stake
    Traded Dec 12, 2025 Filed Jan 22

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 7.01,8.01,9.01
8-K 3.01,8.01,9.01
10-Q
8-K 1.01,5.02,5.07,9.01
DEF 14A
DEFA14A
8-K 7.01,8.01,9.01
10-Q
8-K 8.01,9.01
8-K 8.01,9.01
8-K 5.08,9.01
10-K
8-K 8.01,9.01
8-K 1.01,9.01
SCHEDULE 13G —
8-K 7.01,9.01
8-K 5.02,9.01
8-K 8.01,9.01
10-Q
8-K 1.01,3.01,7.01,9.01
8-K 5.02,9.01
8-K 8.01,9.01
10-Q
SCHEDULE 13G —
424B5

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.